PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: petvivo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/12/2021 | $7.00 | Buy | ThinkEquity |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
SCHEDULE 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
10-K - PetVivo Holdings, Inc. (0001512922) (Filer)
NT 10-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
SCHEDULE 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
Fastest customizable press release news feed in the world
MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently entered into note conversion agreements ("Conversion Agreements") with four existing shareholders of the Company to convert the outstanding balances of fourteen promissory notes ("Notes") having an aggregate debt outstanding of $2,018,155 consisting of principal amount of $1.850,000, plus total accr
On-demand programs deliver clinically relevant science, technical instruction, and case applications in small animal and equine practice MINNEAPOLIS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, a subsidiary of PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and a veterinary medical device company pioneering intra-articular and regenerative solutions, announces the launch of three new continuing education (CE) courses for veterinary professionals. Each RACE-approved program (1.0 credit hour) is designed to help veterinarians deepen their expertise in osteoarthritis (OA), joint injection techniques, and regenerative modalities for canine and equine patients. The courses -
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please schedule 1x1 meetings here "We are excited to highlight today's innovators from the life scienc
MINNEAPOLIS, Sept. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), working in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., (collectively "PetVivo" or the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, announced today that John Lai, Chief Executive Officer of PetVivo, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. DATE: September 18, 2025 TIME: Thursday, September 18th: 11:00 – 11:30 am ET LINK: REGISTER HERE Available for 1x1 mee
MINNEAPOLIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) (collectively referred to herein as "PetVivo"), is an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Nupsala Limited ("Nupsala"). Nupsala will inventory, market and promote PetVivo's veterinary medical device, Spryng® with OsteoCushion® technology, throughout the United Kingdom. Nupsala's sales and marketing activities will commence on September 1, 2025.
MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTC ID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted. The company will hold a conference call today, August 14, 2025, at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q1
MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal First Quarter 2026 conference call information is as follows: Date: Thursday, August 14, 2025 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific t
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, such as Spryng® with OsteoCushion® Technology and PrecisePRP®, today announced that the Company has qualified to trade on the OTCQX® Best Market. PetVivo Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market. PetVivo Holdings Inc. begins trading today on OTCQX under the symbol "PETV." U.S. investors can find cu
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced PetVivo Holdings Inc. (OTCQX:PETV), an emerging biomedical device company, has qualified to trade on the OTCQX® Best Market. PetVivo Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market. PetVivo Holdings Inc. begins trading today on OTCQX under the symbol "PETV." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, c
Live Leadership Updates
Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t
PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts. For the past 20 years, Mr. Eldred served as President of North American Operations for Dech
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor Walker to the new position of field veterinary business development manager for the entire state of Louisiana and the southern region of Texas. "Skylor's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other hydrogel injectable products enables us to prioritize and better address the veterinarians and clinics in our sales pipeline."
Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services veterinarian. Dr. Husby brings to PetVivo more than a decade of experience and accomplishment in animal health. This has involved clinical practice and research experience at
MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. "Adding Anthony to our sales and distribution team provides a tremendous boost to PetVivo's commercialization efforts," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Anthony brings to PetVivo a wealth of
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Eric Samples has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover Ohio, Pennsylvania, and the Baltimore/DC area of the United States. "We are incredibly excited to add Eric to our sales and distribution team," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "The experience Eric brings to PetVivo is extraordinarily va
MINNEAPOLIS, MN, US, June 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, has appointed Bryan Monninger to vice president of sales. In this new position, he will lead the PetVivo's sales and distribution teams, with a focus on expanding the market adoption of the company's innovative animal osteoarthritis medical product, Spryng™ with OsteoCushion™ Technology. Monninger brings to PetVivo more than 20 years of experience in sales and marketing, including senior executive positions at NOVUS and Lintbells, and the Fo
MINNEAPOLIS, MN, US, June 04, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that April Boyce has accepted a position with the Company as its new Vice President of Marketing. "We are thrilled to have April join the PetVivo team and apply her vast insight and expertise to introduce and enhance the overall awareness and image of PetVivo and the products PetVivo commercializes." said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "April brings a wealth of experience to our team as
MINNEAPOLIS, MN, US, March 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ:PETV, PETVW))) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Garry Lowenthal has accepted a position with the Company as its new Chief Financial Officer. "We are incredibly excited to have Garry join the PetVivo management team and provide his well-recognized expertise to further the overall mission of PetVivo." said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Mr. Lowenthal brings a wealth of experience to our team as an expert i
This live feed shows all institutional transactions in real time.
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13D/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13D - PetVivo Holdings, Inc. (0001512922) (Subject)
Live finance-specific insights
MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTC ID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted. The company will hold a conference call today, August 14, 2025, at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q1
MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal First Quarter 2026 conference call information is as follows: Date: Thursday, August 14, 2025 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific t
MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB:PETV, OTC:PETVW), a leading biomedical company delivering innovative medical therapeutics for equines and companion animals, reported results for its fiscal year ended March 31, 2025. All comparisons are to the previous fiscal year period unless otherwise noted. The company has filed for an extension for the filing of its Form 10-K for the fiscal year ending March 31, 2025, therefore all financial results reported in this press release are unaudited preliminary estimates, and are subject to change. The company will hold a conference call today at
MINNEAPOLIS, MN, US, June 26, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Monday, June 30, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal fourth quarter and year ended March 31, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. Date: Monday, June 30, 2025 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time) Toll-free dial-in number: +1 253 205 0468 Conference ID: 83424004566 Passc
MINNEAPOLIS, MN, US, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), a leading biomedical company delivering innovative therapeutics and medical devices for equines and companion animals, reported results for its fiscal third quarter ended December 31, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call today at 3:00 p.m. Eastern time to discuss the results for the period (see dial-in information below). Fiscal Q3 2025 Financial Highlights Revenues totaled $583,000, up 191% sequentially and declined 2% from the same year ago period, reflecting the company's continued efforts from targetin
MINNEAPOLIS, MN, US, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Friday, February 14, 2025 after market close. The company will host a conference call to discuss these results at 2:00 p.m. CT (3:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=b5c71aaf-5545-4297-93c3-e23bfb001608. A replay of the
MINNEAPOLIS, MN, US, Dec. 30, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will host a live webcast Shareholders Update Meeting to provide an overview of the Company's progress in the 2025 fiscal year and a look into the potential future of the Company. The Shareholders Update Meeting: 2025 Company Overview will be held on Wednesday, January 8, 2025 at 3:30 p.m. CT (4:30 p.m. ET). Attendees of the Shareholders Update Meeting live webcast and conference call can register and access the webcast on PetVivo's Investor Relations website at: https://audience.m
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time November 14, 2024 to discuss the results (see dial-in information below). Fiscal Q2 2025 Financial Highlights Revenues totaled $201,000, up 62% sequentially and down 3% from the same year ago period, as the company continued to transition in the current fiscal yea
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 14, 2024 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=6fd4ce0f-76b5-4819-9fd7-a8412e31847e A replay of the webcast wi
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal first quarter ended June 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time August 14, 2024 to discuss the results (see dial-in information below). Fiscal Q1 2025 Financial Highlights Revenues increased 6% to $124,000, driven by the increasing roll out and adoption of